MAX SENNA MANO
Projetos de Pesquisa
Unidades Organizacionais
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
- Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis(2020) MANO, Max S.; LOIBL, Sibylle; MAMOUNAS, Eleftherios P.; MINCKWITZ, Gunter von; HUANG, Chiun-Sheng; UNTCH, Michael; WOLMARK, Norman; WAPNIR, Irene L.; YANG, Youngsen; CONLIN, Alison K.; KUEMMEL, Sherko; SAGHATCHIAN, Mahasti; DIGIOVANNA, Michael P.; STRUNK, Claudia; ZIMOVJANOVA, Martina; SONG, Chunyan; LIU, Haying; TESAROWSKI, David; BLOTNER, Steven; LAM, Lisa H.; SMITT, Melanie; GEYER JR., Charles E.
- Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer(2020) CONTE, PierFranco; SCHNEEWEISS, Andreas; LOIBL, Sibylle; MAMOUNAS, Eleftherios P.; MINCKWITZ, Gunter von; MANO, Max S.; UNTCH, Michael; HUANG, Chiun-Sheng; WOLMARK, Norman; RASTOGI, Priya; D'HONDT, Veronique; REDONDO, Andres; STAMATOVIC, Ljiljana; BONNEFOI, Herve; CASTRO-SALGUERO, Hugo; FISCHER, Hans H.; WAHL, Tanya; SONG, Chunyan; BOULET, Thomas; TRASK, Peter; GEYER JR., Charles E.Background The phase 3 KATHERINE trial demonstrated significantly improved invasive disease-free survival with adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant chemotherapy plus HER2-targeted therapy. Methods Patients who received taxane- and trastuzumab-containing neoadjuvant therapy (with/without anthracyclines) and had residual invasive disease (breast and/or axillary nodes) at surgery were randomly assigned to 14 cycles of adjuvant T-DM1 (3.6 mg/kg intravenously every 3 weeks) or trastuzumab (6 mg/kg intravenously every 3 weeks). The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and breast cancer module (QLQ-BR23) were completed at screening, at day 1 of cycles 5 and 11, within 30 days after study drug completion, and at 6- and 12-month follow-up visits. Results Of patients who were randomly assigned to T-DM1 (n = 743) and trastuzumab (n = 743), 612 (82%) and 640 (86%), respectively, had valid baseline and >= 1 postbaseline assessments. No clinically meaningful changes (>= 10 points) from baseline in mean QLQ-C30 and QLQ-BR23 scores occurred in either arm. More patients receiving T-DM1 reported clinically meaningful deterioration at any assessment point in role functioning (49% vs 41%), appetite loss (38% vs 28%), constipation (47% vs 38%), fatigue (66% vs 60%), nausea/vomiting (39% vs 30%), and systemic therapy side effects (49% vs 36%). These differences were no longer apparent at the 6-month follow-up assessment, except for role functioning (23% vs 16%). Conclusion These data suggest that health-related quality of life was generally maintained in both study arms over the course of treatment.
conferenceObject Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.(2020) DENKERT, Carsten; LAMBERTINI, Chiara; FASCHING, Peter A.; POGUE-GEILE, Katherine L.; MANO, Max S.; UNTCH, Michael; WOLMARK, Norman; HUANG, Chiung-Sheng; LOIBL, Sibylle; MAMOUNAS, Eleftherios P.; MINCKWITZ, Gunter Von; GEYER, Charles E.; BOULET, Thomas; SONG, Chunyan; PHILLIPS, Gail Lewis; NOWICKA, Malgorzata; HAAS, Sanne de; BASIK, Mark- Prevalence of patients with indication of genetic evaluation for hereditary breast and ovarian syndrome in the Brazilian cohort study - AMAZONA III(2020) SOUZA, Alessandra BorbaAnton de; ROSA, Daniela; FRASSON, Antonio Luiz; ZERWES, Felipe Pereira; ROSSATO, Nathalia Cunha; ASTHON-PROLLA, Patricia; SIMON, Sergio; BINES, Jose; BARRIOS, Carlos; MORELLE, Alessandra; ALBERTOSAMPAIO FILHO, Carlos; MANO, Max; GOMES, Rafaela; WERUTSKY, Gustavo